Dermal Fillers
REVANESSE references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
CE Marked
SKU 11115
Revanesse Ultra™+
In stock
Volume
2 x 1,2 mL
Laboratory
Prollenium Medical Technologies Inc.
Origin
Canada
Indication
Deeper wrinkle correction, volume restoration and facial contouring
Treatment areas
Trade price and history are verified-only
allpara supplies licensed practitioners. Sign in or apply for a B2B account to see live pricing, volume tiers and price history.
Revanesse Ultra+ is a colourless, odourless, transparent aqueous gel of synthetic origin from Prollenium Medical Technologies in Aurora, Canada. It carries cross-linked hyaluronic acid at 25 mg/mL with 0.3% lidocaine in phosphate-buffered saline, cross-linked with BDDE. It is indicated for the treatment of facial rhytides and lipoatrophy by injection into the skin, with an implantation life averaging 6 to 12 months. Each box contains two 1.2 mL syringes with up to two sterilised 27G needles.
Key Benefits of Revanesse Ultra™+
- Cross-linked hyaluronic acid 25 mg/mL with 0.3% lidocaine for injection comfort
- Indicated for facial rhytides and for lipoatrophy
- Injected into the skin, with the plane chosen by the practitioner
- Implantation life averages 6 to 12 months
- Supplied as two 1.2 mL pre-filled syringes with up to two sterilised 27G needles
- BDDE cross-linked in phosphate-buffered saline
- CE marked 0653 for the syringe, with CE 0123 needles
Indications and Professional Use
Main indications
- Facial rhytides
- Lipoatrophy
Professional use
For professional use. Revanesse Ultra+ should only be injected by or under the direct supervision of qualified physicians trained in the proper injection technique for filling facial wrinkles, and is not for retail sale or self-administration. The area must be thoroughly disinfected and injection performed under sterile conditions; bring the product to room temperature for 30 minutes beforehand, prime the syringe until a small drop appears at the needle tip, and inject slowly with the least pressure necessary. If the skin blanches, stop immediately and massage until normal colour returns. It must not be injected into an area already containing another filler or a permanent implant, and must not contact quaternary ammonium salts such as benzalkonium chloride. Store between 2 and 25 degrees Celsius, protected from direct sunlight and freezing.
Treatment areas
- Face
Patient profile
For adult patients seeking treatment of facial rhytides or lipoatrophy, as assessed by a qualified physician. Because it contains lidocaine, it is contraindicated in patients with hypersensitivity to any amide-type local anaesthetic. Further contraindications include hypertrophic scarring, acne or other inflammatory skin disease, acute or chronic skin disease at or near the injection site, auto-immune disorders or immunotherapy, multiple severe allergies, coagulation defects or anti-coagulation therapy, sensitivity to hyaluronic acid, and unattainable expectations. It contains trace amounts of gram-positive bacterial proteins and is contraindicated in patients allergic to such material. It must not be used during pregnancy or lactation, in anyone under 18, or in conjunction with laser, intense pulsed light, chemical peeling or dermabrasion.
How Revanesse Ultra™+ Works
Ultra+ is a cross-linked hyaluronic acid gel that occupies volume in the tissue where it is placed, correcting facial rhytides and the volume loss of lipoatrophy. Unlike the middle-dermis references in the range, its indication is written for injection into the skin without specifying a single plane, so how long it lasts depends on the depth and location the practitioner chooses, which is why the manufacturer gives a range of 6 to 12 months. The 0.3% lidocaine is present for injection comfort, which makes hypersensitivity to amide-type anaesthetics an outright contraindication.
Why Order From Allpara
Allpara offers genuine, verified REVANESSE products from vetted suppliers, with full batch-traceability and expert support. We serve clinics and aesthetic professionals with CE-certified products, fast EU-wide delivery from our EU warehouse, and competitive trade pricing. Our focus is your patients' safety, satisfaction and results - with dedicated after-sales support for your peace of mind.
Frequently Asked Questions
How does Ultra+ differ from Outline+, Shape+ and Contour+?
Placement. All four carry 25 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine and last 6 to 12 months. Outline+, Shape+ and Contour+ are all specified for the middle part of the dermis and for medium to deep rhytides; Ultra+ is written for injection into the skin without a single specified plane, and for facial rhytides generally.
What should a practitioner do if the skin blanches during injection?
Stop the injection immediately and massage the area until the skin returns to its normal colour. Blanching can signal intravascular placement, which has been associated with embolisation, vision impairment, blindness, skin necrosis and stroke.
Where can clinics buy Revanesse Ultra+?
ALLPARA supplies Revanesse Ultra+ to licensed practitioners, clinics and distributors on a B2B account. Wholesale terms, stock position and batch expiry are released to registered professional buyers.
More from Prollenium Medical Technologies
Clinic alternatives
/ Recently viewed
Pick up where you left off
Revanesse Ultra™+
In stock
CE Marked
Revanesse Ultra+ is a colourless, odourless, transparent aqueous gel of synthetic origin from Prollenium Medical Technologies in Aurora, Canada. It carries cross-linked hyaluronic acid at 25 mg/mL with 0.3% lidocaine in phosphate-buffered saline, cross-linked with BDDE. It is indicated for the treatment of facial rhytides and lipoatrophy by injection into the skin, with an implantation life averaging 6 to 12 months. Each box contains two 1.2 mL syringes with up to two sterilised 27G needles.
Key Benefits of Revanesse Ultra™+
- Cross-linked hyaluronic acid 25 mg/mL with 0.3% lidocaine for injection comfort
- Indicated for facial rhytides and for lipoatrophy
- Injected into the skin, with the plane chosen by the practitioner
- Implantation life averages 6 to 12 months
- Supplied as two 1.2 mL pre-filled syringes with up to two sterilised 27G needles
- BDDE cross-linked in phosphate-buffered saline
- CE marked 0653 for the syringe, with CE 0123 needles
Indications and Professional Use
Main indications
- Facial rhytides
- Lipoatrophy
Professional use
For professional use. Revanesse Ultra+ should only be injected by or under the direct supervision of qualified physicians trained in the proper injection technique for filling facial wrinkles, and is not for retail sale or self-administration. The area must be thoroughly disinfected and injection performed under sterile conditions; bring the product to room temperature for 30 minutes beforehand, prime the syringe until a small drop appears at the needle tip, and inject slowly with the least pressure necessary. If the skin blanches, stop immediately and massage until normal colour returns. It must not be injected into an area already containing another filler or a permanent implant, and must not contact quaternary ammonium salts such as benzalkonium chloride. Store between 2 and 25 degrees Celsius, protected from direct sunlight and freezing.
Treatment areas
- Face
Patient profile
For adult patients seeking treatment of facial rhytides or lipoatrophy, as assessed by a qualified physician. Because it contains lidocaine, it is contraindicated in patients with hypersensitivity to any amide-type local anaesthetic. Further contraindications include hypertrophic scarring, acne or other inflammatory skin disease, acute or chronic skin disease at or near the injection site, auto-immune disorders or immunotherapy, multiple severe allergies, coagulation defects or anti-coagulation therapy, sensitivity to hyaluronic acid, and unattainable expectations. It contains trace amounts of gram-positive bacterial proteins and is contraindicated in patients allergic to such material. It must not be used during pregnancy or lactation, in anyone under 18, or in conjunction with laser, intense pulsed light, chemical peeling or dermabrasion.
How Revanesse Ultra™+ Works
Ultra+ is a cross-linked hyaluronic acid gel that occupies volume in the tissue where it is placed, correcting facial rhytides and the volume loss of lipoatrophy. Unlike the middle-dermis references in the range, its indication is written for injection into the skin without specifying a single plane, so how long it lasts depends on the depth and location the practitioner chooses, which is why the manufacturer gives a range of 6 to 12 months. The 0.3% lidocaine is present for injection comfort, which makes hypersensitivity to amide-type anaesthetics an outright contraindication.
Why Order From Allpara
Allpara offers genuine, verified REVANESSE products with full batch-traceability, CE-certified stock, fast EU-wide delivery and expert after-sales support.
Frequently Asked Questions
How does Ultra+ differ from Outline+, Shape+ and Contour+?
Placement. All four carry 25 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine and last 6 to 12 months. Outline+, Shape+ and Contour+ are all specified for the middle part of the dermis and for medium to deep rhytides; Ultra+ is written for injection into the skin without a single specified plane, and for facial rhytides generally.
What should a practitioner do if the skin blanches during injection?
Stop the injection immediately and massage the area until the skin returns to its normal colour. Blanching can signal intravascular placement, which has been associated with embolisation, vision impairment, blindness, skin necrosis and stroke.
Where can clinics buy Revanesse Ultra+?
ALLPARA supplies Revanesse Ultra+ to licensed practitioners, clinics and distributors on a B2B account. Wholesale terms, stock position and batch expiry are released to registered professional buyers.
More from Prollenium Medical Technologies
View laboratory →* Professional-use product. Packaging may vary by batch or market. Refer to the supplied IFU for full directions and contraindications.